BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

  September 16, 2024

   · 

  12 min read
• Press Releases

  Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024

  September 16, 2024

   · 

  2 min read
• Press Releases

  Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

  September 16, 2024

   · 

  2 min read
• Press Releases

  Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

  September 16, 2024

   · 

  10 min read
• Press Releases

  Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

  September 16, 2024

   · 

  9 min read
• Press Releases

  FDA Roundup: September 13, 2024

  September 16, 2024

   · 

  3 min read
• Press Releases

  Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 13, 2024

  September 16, 2024

   · 

  3 min read
• Press Releases

  Albert Einstein College of Medicine Receives Major Federal Grant to Help Lead National Effort for Pandemic Preparedness

  September 16, 2024

   · 

  6 min read
• Press Releases

  CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 13, 2024

  September 16, 2024

   · 

  3 min read
• Press Releases

  iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

  September 16, 2024

   · 

  10 min read